These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1889187)

  • 21. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT; Prignano G; Iegri F; Lorenzi A
    Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An in-vitro comparison of new cephalosporins with special reference to Pseudomonas aeruginosa.
    van Klingeren B
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():97-105. PubMed ID: 19810171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates.
    Barry AL; Brown SD; Novick WJ
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2193-6. PubMed ID: 8619565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland.
    Liassine N; Bille J; Breer C; Frei R; Wüst J; Auckenthaler R
    Scand J Infect Dis; 1997; 29(6):615-21. PubMed ID: 9571744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1985 Jul; 28(1):160-2. PubMed ID: 3929677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of new cephalosporins against multi-resistant gram-negative bacteria.
    Fainstein V; Le Blanc B; Bodey GP
    Infection; 1983; 11 Suppl 1():S20-2. PubMed ID: 6832840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
    Giamarellos-Bourboulis EJ; Grecka P; Tsitsika A; Tympanidou C; Giamarellou H
    Diagn Microbiol Infect Dis; 2000 Mar; 36(3):185-91. PubMed ID: 10729661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in vitro activities of third-generation cephalosporins.
    Fass RJ
    Arch Intern Med; 1983 Sep; 143(9):1743-5. PubMed ID: 6615095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro activity of first, second and third generation cephalosporins.
    Forsgren A
    Acta Pathol Microbiol Scand B; 1981 Aug; 89(4):221-5. PubMed ID: 6274143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Susceptibility of some bacteria isolated from clinical samples to third-generation cephalosporins].
    Willke A; Tural D
    Mikrobiyol Bul; 1987 Oct; 21(4):279-83. PubMed ID: 3332704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria.
    Thornsberry C
    Am J Med; 1985 Aug; 79(2A):14-20. PubMed ID: 3927723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The activity of cefpirome and ten other antibacterial agents against 2858 clinical isolates collected from 20 centres.
    Reeves DS; Bywater MJ; Holt HA
    J Antimicrob Chemother; 1993 Mar; 31(3):345-62. PubMed ID: 8486569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of bacterial resistance to the third generation cephalosporins and their clinical use.
    Kolár M; Látal T; Hájek V
    J Chemother; 1999 Aug; 11(4):260-5. PubMed ID: 10465127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
    Corser CA; Day GJ; Humble MW
    N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [An analysis of bacterial resistance to antimicrobial agents in a burn centre].
    Xu W; Sun Z; Chen X
    Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi; 1998 May; 14(3):199-202. PubMed ID: 10452066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
    Bauernfeind A
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
    Cheng AF; Ling TK; Lam AW; Fung KS; Wise R
    J Antimicrob Chemother; 1993 May; 31(5):699-709. PubMed ID: 8335498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.